RE:RE:RE:RE:New PR Announcing Initiation of Basket Trial They give no data, but at the same time they talk about firmly believing, about advantage, about potential, but they come up with nothing to back that. All we know is that they were able to give 30% more than the MTD of docetaxel alone for one cycle. So nothing there about cummulative toxicity. Sorry, this is not serious. It is join us as belivers in the potential based on test on mice. We will not disclose anything about what we saw on humans. It is highly likely that they did not see any real efficacy.
We firmly believe that the unique mechanism of entry of TH1902 in cancer cells is a key advantage to improve the therapeutic window of docetaxel. TH1902's targeted delivery and rapid internationalization in cancer cells via the Sortilin receptor enables the potential to accumulate 7.5 to 10 times more docetaxel in cancer cells - as compared to the administration of docetaxel alone. jfm1330 wrote: So they did it, a freakin PR with no details on phase Ia. Nothing. We are completely in the dark.
Wino115 wrote: At least we know it's done, no issues, and on to the more interesting and informing part of the basket trial. I'll take that.
1. "..firmly believe" the cell entry is an advantage, so they may have (very speculative) seen data around chemo not going anywhere, thus it must be into the cell.
2. Continue to develop other anti-cancer agents, so maybe they're further along...please tell us!
3. "NO DLTs" - We thought this would be the case, but it is very positive to start your first in human efficacy trials with a NO DLT label. We know some of the ADCs had issues that delayed them and required counter-medications to control some of the DLTs. It's at least a good starting point.
Let the Trials Begin!
Hopefully someone at the meeting in a few hours can tell us more.
palinc2000 wrote: The only new news even though it was expected is that the last 6 patients did not have any serious adverse effects...The rest of the PR is almost old news